The FDA De Novo authorized BioFire RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

The BIOFIRE RP2.1 Panel is a frontline test to help clinicians more quickly diagnose URTIs, including COVID-19, influenza, RSV, and many others. The multiplex PCR panel identifies 22 …

The BioFire Respiratory 2.1 Panel (RP2.1) is a multiplex polymerase chain reaction (PCR) test that identifies nucleic acids from 23 difer-ent bacteria and viruses that commonly cause upper …

The BIOFIRE System is the new standard for syndromic infectious disease diagnostics. Simple, fast, and comprehensive, the BIOFIRE System delivers accurate results in about one hour.

The BioFire RP2.1 is a real-time, nested multiplexed polymerase chain reaction test designed to simultaneously identify nucleic acids from 22 different viruses and bacteria associated with ...

Designed with the syndromic approach in mind, each panel can detect a broad grouping of probable pathogenic causes in a single, rapid test. The BioFire Panels test for viruses, …

May 24, 2022 · You are being given this Fact Sheet because your sample(s) was tested for the Coronavirus Disease 2019 (COVID-19) using the BioFire COVID-19 Test. This Fact Sheet …

Point-of-care respiratory testing solutions with BIOFIRE® SPOTFIRE® Respiratory Panels offering rapid syndromic PCR tests for a range of common pathogens.

May 24, 2022 · The EUA (Emergency Use Authorization) for the BioFire COVID-19 Test enables CLIA moderate and high complexity laboratories to conduct a PCR test for SARS-CoV-2 in …

The BioFire Respiratory 2.1 Panel (RP2.1) is a multiplex polymerase chain reaction (PCR) test that identifies nucleic acids from 23 different bacteria and viruses that commonly cause upper …